Stem definition | Drug id | CAS RN |
---|---|---|
calcium channel blockers, nifedipine derivatives | 1532 | 103890-78-4 |
Molecule | Description |
---|---|
Synonyms:
|
|
Dose | Unit | Route |
---|---|---|
4 | mg | O |
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 18 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
None
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Procalcitonin abnormal | 58.72 | 41.45 | 10 | 978 | 302 | 29573237 |
Encephalomalacia | 49.93 | 41.45 | 10 | 978 | 743 | 29572796 |
Acquired macroglossia | 47.54 | 41.45 | 6 | 982 | 18 | 29573521 |
PO2 decreased | 43.34 | 41.45 | 10 | 978 | 1449 | 29572090 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Procalcitonin abnormal | 61.58 | 31.35 | 10 | 1590 | 305 | 64496827 |
Encephalomalacia | 49.18 | 31.35 | 10 | 1590 | 1081 | 64496051 |
Drug interaction | 48.88 | 31.35 | 52 | 1548 | 362031 | 64135101 |
International normalised ratio increased | 40.73 | 31.35 | 25 | 1575 | 79142 | 64417990 |
PO2 decreased | 40.11 | 31.35 | 10 | 1590 | 2703 | 64494429 |
Lymphocyte count increased | 38.55 | 31.35 | 11 | 1589 | 4964 | 64492168 |
Scrotal oedema | 36.75 | 31.35 | 8 | 1592 | 1199 | 64495933 |
Acquired macroglossia | 36.23 | 31.35 | 6 | 1594 | 207 | 64496925 |
PCO2 decreased | 34.55 | 31.35 | 9 | 1591 | 2893 | 64494239 |
Device related sepsis | 33.75 | 31.35 | 10 | 1590 | 5145 | 64491987 |
None
Source | Code | Description |
---|---|---|
ATC | C08CA09 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002121 | Calcium Channel Blockers |
MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D049990 | Membrane Transport Modulators |
None
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.23 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Voltage-gated L-type calcium channel | Ion channel | BLOCKER | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
Cytochrome P450 3A4 | Enzyme | IC50 | 6.05 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.25 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 5.68 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.64 | DRUG MATRIX | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 5.70 | DRUG MATRIX | |||||
Thromboxane-A synthase | Enzyme | IC50 | 5.77 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 5.70 | DRUG MATRIX | |||||
Androgen receptor | Transcription factor | Ki | 5.58 | DRUG MATRIX |
ID | Source |
---|---|
4025250 | VUID |
N0000179165 | NUI |
D04657 | KEGG_DRUG |
4025250 | VANDF |
C0064568 | UMLSCUI |
CHEBI:135737 | CHEBI |
CHEMBL460291 | ChEMBL_ID |
DB09236 | DRUGBANK_ID |
C060285 | MESH_SUPPLEMENTAL_RECORD_UI |
11740 | IUPHAR_LIGAND_ID |
6093 | INN_ID |
260080034N | UNII |
5311217 | PUBCHEM_CID |
28382 | RXNORM |
004453 | NDDF |
319299000 | SNOMEDCT_US |
395764001 | SNOMEDCT_US |
None